The weight loss drug boom and what it means for employers GLP-1 drug demand: What employers need to know Weight loss medications are changing the health care landscape
An example is the influence of the gut on neurotransmitters and vice versa is the abovementioned monoaminergic system [76, 87, 232], where reduced DA and adrenaline in the gut, which led to a decrease in anxiety-like behavior, indicating probably a link of these neurotransmitters with behavior
DF: Writing original draft, Supervision, Data curation
Theyre science-backed, powerful, and increasingly popular among people looking to support long-term health goals
It means there is no real evidence for their benefits there is no information regarding their safety, and the long-term effects of the substances are unknown
However, this approach is based on anecdotal patient experience rather than robust clinical evidence, and individual responses vary considerably